Obesity After 65 in India

The condition that changes the whole picture in older age is sarcopenic obesity: carrying too much body fat and too little muscle strength at once. An ESPEN and EASO consensus defines it as excess adiposity alongside low skeletal muscle mass or function, "fat and weak" together, not simply overweight.

This matters after 65 because ageing quietly rearranges the body. Geriatric pharmacology reviews describe a typical 20 to 40% increase in body fat and a 10 to 15% decrease in lean body mass and total body water, even when total weight barely changes. Fat also moves inward, into the abdomen, liver, and muscle.

For many older Indians this sits on top of decades of metabolic disease. Many South Asians are diagnosed with type 2 diabetes in midlife, so by their late sixties they have often carried insulin resistance for twenty years or more. With inactivity over that duration, muscle breakdown and fat infiltration both accelerate, the biology of metabolic disease compounding over time.

Sarcopenic obesity is not a rare edge case in India. In the LASI wave-1 analysis of 72,250 adults aged 45 and older, the weighted prevalence of obesity, sarcopenia, and sarcopenic obesity was 27.1%, 41.9%, and 8.7% respectively, using Asian Working Group and modified Asian BMI criteria.

The picture is sharper in people who already have diabetes. In a hospital cohort of 151 Indian adults with type 2 diabetes, sarcopenic obesity was reported in 44%, linked to older age, low physical activity, and poorer glycaemic control. India still lacks standardised, population-specific cut-offs for muscle strength and mass, and a 2025 Indian consensus has called for exactly those thresholds.

Diet compounds the risk. A survey of 1,260 adults aged 30 to 55 across seven cities found over 80% of Indian diets fell short of 1 g/kg/day of protein, vegetarians more so than non-vegetarians.

Here the evidence becomes genuinely contested. The "obesity paradox" describes a counterintuitive finding: in some older populations, overweight or mildly obese people appear to outlive those at "normal" weight. In a study of 4,551 adults with a mean age of 74, followed for around 11 years, metabolically healthy class I obesity (BMI 30 to 34.9) carried a hazard ratio of 0.58 (95% CI 0.42 to 0.80) for all-cause mortality, a signal of lower, not higher, risk.

The counter-argument is that much of this is a mirage of study design. Critics point to four problems:

• Reverse causation: illnesses such as cancer, COPD, and heart failure cause weight loss before people are measured, so low BMI can be a marker of hidden disease rather than a cause of death.
• Smoking confounding: smokers tend to be leaner and die earlier. Studies that adjust poorly for smoking make thinness look more dangerous than it is.
• Collider bias: selecting a cohort by survival to old age or by existing disease can manufacture a protective association that does not exist in the general population.
• BMI cannot separate muscle from fat: two people at the same BMI can have very different amounts of muscle, and muscle is what predicts survival.

The honest position, which the literature itself takes, is that the paradox is unresolved. No serious reading of it justifies gaining weight to live longer.

Intentional weight loss is not always the wrong move after 65. It is conditional. In a landmark trial by Villareal and colleagues, obese adults aged 65 and older who combined a six-month weight-loss and exercise programme improved their frailty scores, physical performance, and quality of life more than diet or exercise alone. When weight comes off with resistance exercise and enough protein to protect muscle, it can improve blood pressure, blood sugar, and function in carefully selected older people.

The harm sits on the other side of that "with." Weight loss in older adults reliably strips away lean mass and bone alongside fat, even when exercise is included. One analysis in postmenopausal women found that intentional weight loss raised the risk of frailty fractures at the hip, spine, and wrist. Lost muscle means slower walking, weaker recovery from illness, and more falls. For someone already sarcopenic, dieting can tip a fragile balance into disability.

That is why, for several groups, the evidence supports a genuine "do not attempt intentional weight loss": not a softened caveat on a weight-loss plan, but a different plan entirely.

Weight loss is discouraged for certain groups of older adults because it may increase health risks:

• Existing sarcopenia or sarcopenic obesity: Further weight loss can accelerate muscle wasting and increase the risk of falls and disability. Preserving muscle should be the priority.
• Underweight or low-BMI older adults: These groups already have higher all-cause and respiratory mortality risks. Losing more weight can worsen outcomes.
• Recent unintentional weight loss (more than 5–10% over 6–12 months): This may indicate an undiagnosed illness or malnutrition. Identifying the cause should come before starting a diet.
• Advanced frailty or high fracture risk: Weight loss can further reduce bone density. Fall prevention, strength and adequate nutrition should come first.

In these situations, maintaining a stable weight while building strength should be the priority. A slight weight increase from added muscle may also be beneficial.

Older adults with obesity rarely take just one medication. Polypharmacy, commonly five or more medicines, is normal in this group and interacts with weight in ways that are easy to miss. The concern is not the weight-loss drugs themselves, but the everyday medicines for blood pressure, diabetes, thyroid, cholesterol, or clotting.

As lean mass and body water fall and fat rises with age, the volume a drug distributes into changes. Water-soluble drugs can reach higher concentrations. Fat-soluble ones linger longer. And kidney and liver clearance slow with age, so a dose that was right last year may no longer be.

Reviews note that significant weight loss, new frailty, or malnutrition should prompt a medication review, with special care for narrow-margin drugs such as warfarin. Nobody should adjust these alone: anyone over 65 losing meaningful weight should have their prescriptions and blood tests reviewed by their clinician.

Because the scale is unreliable here, the useful measurements are of strength and function. Handgrip strength and gait speed are core, validated markers. Low grip and slow walking predict falls, hospitalisation, and death. The SARC-F questionnaire, a five-item self-report on strength and mobility, works as a bedside screen. In an Indian study of 300 patients aged 65 and older, it showed 73.2% sensitivity and 86.5% positive predictive value for sarcopenia. Where available, DXA or bioelectrical impedance confirms muscle and fat mass. Otherwise, calf circumference is a rough proxy.

An older adult or caregiver should consider a specialist assessment (from a geriatrician, endocrinologist, or clinical nutrition service) when any of these appear:

• A high SARC-F score, low grip strength, or slow gait speed alongside weakness or recent falls.
• Unintentional weight loss of more than 5 to 10% over 6 to 12 months.
• A BMI in the underweight range, or a clear drop in calf circumference.
• Known diabetes with declining function, difficulty on stairs, frequent falls, or marked fatigue, despite adequate sugar control.

None of these thresholds is a diagnosis, and this article cannot make one. They are prompts to seek guidance from a geriatrician or endocrinologist, who can assess body composition, bone density, medications, and function together.

For many older Indians with long-standing metabolic disease, the most evidence-aligned goal is not a lighter body but a stronger one. The practical steps, in order of priority:

1. Make resistance training the foundation: Working muscles against load, from resistance bands to weighted sit-to-stands, is the primary driver of improved muscle mass, strength, and function in older adults. Meta-analyses of adults aged 50 and older find that pairing resistance work with adequate protein improves lean mass and strength more than protein alone.
2. Spread protein across all meals: Reviews suggest older adults at risk of sarcopenia aim for roughly 1.0 to 1.3 g/kg/day, at 25 to 30 g per meal, with little added benefit beyond about 1.6 g/kg/day. These figures come from mostly Western data, not India-specific trials, so treat them as a direction to individualise with a clinician.
3. Track function, not the scale: Monitor strength, walking speed, and balance rather than body weight. If grip strength or the ability to climb stairs falls during any weight-change effort, that is a signal to adjust the plan.
4. Request a medication review if weight changes significantly: Whether you are losing or gaining, a clinician should check that existing prescriptions still make sense for your new body composition.

The goal is strength, not just a lighter body:

If you or a parent is over 65, living with obesity or long-standing diabetes, and unsure whether losing weight would help or harm, the safest next step is a body-composition and frailty assessment that reviews muscle, function, and existing medicines together. A Voy clinician-led consultation can build a plan around staying strong, not simply lighter. For context on how these trade-offs differ a decade earlier, see our companion piece on obesity from 50 to 65.

This article is for general information and education only and is not medical advice, diagnosis, or treatment. GLP-1 and other medications referenced are prescription-only and are appropriate only for certain people under the supervision of a qualified clinician. Do not start, stop, or change any medication based on this article. Please consult a registered medical practitioner about your individual circumstances. Information reflects what was available at the time of review and may change.